# TRANSCRIPT — R-CLIN-A
model: gpt-5.5-2026-04-23 | reasoning_effort: high | retrieval: full-read | web: DISABLED (no hosted tools) | started: 2026-06-03T21:55:25
docs available: ['INDEX', 'proof', 'ref01', 'ref02', 'ref03', 'ref04', 'ref06', 'ref07', 'ref08', 'ref09', 'ref10', 'ref11', 'ref12', 'ref13', 'ref14', 'ref15', 'ref17', 'ref18', 'ref19', 'ref20', 'ref21', 'ref22', 'ref23', 'ref24']

===== DEVELOPER MESSAGE =====
You are running inside an OFFLINE evaluation harness. You have NO internet access and NO shell. Access documents ONLY through these tools:
- list_docs(): list available document names.
- search_doc(name, query): find passages matching a query (regex/text) with surrounding context.
- read_doc(name, offset, length): read a document, optionally a bounded window.
- write_note(name, content): optional scratch memory.
Documents: 'proof' (the submitted manuscript proof, including its bound supplementary appendix), 'INDEX' (maps each cited reference number to its source), and 'ref01'..'ref24' (full text of each cited reference). References 5 and 16 are NOT provided (no ref05/ref16). When the instructions refer to the manuscript PDF, 'pdfs/INDEX.md', or a reference's PDF, use the matching name (reference 7 -> 'ref07').

Read whatever you need (read_doc returns whole documents by default), then produce your review.

===== USER INSTRUCTION (verbatim) =====
You are serving as a peer reviewer for a general medical journal (the BMJ tier). You have been sent a manuscript reporting a randomized controlled trial and PDFs of the references it cites. You do not have the raw data or the analysis code — review what you have been given, as a reviewer at submission would. Your job is to produce a rigorous, fair, and specific peer-review report that helps the editors decide whether the work is sound and what revisions it needs.

You have no internet access. You are reviewing this manuscript pre-publication; treat the trial's results elsewhere, this paper, and any outside commentary as unavailable. The references the manuscript cites are provided as PDFs in `pdfs/` (an index maps each to its reference number) — consult those directly rather than relying on memory when you need to check what a cited source says.

Ground every point in the manuscript or a cited reference. Do not raise generic concerns you cannot tie to something specific in these materials. Distinguish issues that are major (could change conclusions or require new analysis) from minor (clarity, reporting). Be concrete: cite sections, tables, figures, page numbers, and the specific sentence at issue.

Produce your report in the format specified at the end of these instructions.

## Your role

Your focus is clinical and methodological substance in the maternal-health context: whether the outcomes measured are the ones that matter to women and clinicians; how blood loss is ascertained and how reliable that ascertainment is; the intervention and comparator and their real-world delivery; adverse-event and serious-adverse-event capture; and how this trial sits against the prior evidence base for antifibrinolytics in obstetric bleeding. Tie concerns to specific design choices in the manuscript.

## Your materials

You have been given exactly these, and nothing else (no internet, no raw data, no analysis code, no published version of this paper, no other commentary):

1. **The submitted manuscript proof** — `inputs/27_jan_2026_bmj-2026-089636_proof_hi.pdf`. This is the complete submission. It **includes the supplementary appendix** bound at the end (table of contents plus supplementary tables S1–S14, the per-protocol population detail, supplementary figures, and a pointer to the trial's pre-specified protocol and statistical analysis plan).
2. **The cited references** — the manuscript cites 24 references; their PDFs are in `pdfs/`, mapped reference-number → file in `pdfs/INDEX.md`. **22 of the 24 are present.** Two are unavailable: reference 5 and reference 16. For any point that would rest on one of those two sources, state that you could not check it because the source was not provided, rather than relying on memory.

## Required output format

End your review with these sections, in this order:

1. **Summary** (3–5 sentences: what the trial did, your overall assessment).
2. **Major points** (numbered; each with the specific manuscript/reference location).
3. **Minor points** (numbered).
4. **Anything you verified that checked out** (numbered; what you confirmed against a cited source — so editors know what was checked, not just what failed).
5. **Editorial recommendation** (accept / minor revision / major revision / reject) **with one paragraph of justification.**
6. **What I could not assess** (limits of what you could check with the materials given — e.g., anything needing the raw data).

===== FINAL OUTPUT =====
## 1. Summary

This multicentre, double blind, randomised trial tested 1 g intravenous tranexamic acid versus placebo after cord clamping in 1694 modified intention-to-treat participants with placenta praevia undergoing caesarean delivery in 24 Chinese maternity units. The trial is clinically important and appears to have achieved good treatment adherence and near-complete ascertainment of the primary outcome. The primary trial-defined postpartum haemorrhage outcome was reduced, but much of the clinical interpretation depends on a calculated blood-loss endpoint, while several patient-important severe outcomes were uncommon or not clearly improved. I think the manuscript is potentially publishable, but it needs major revision to clarify blood-loss ascertainment, safety limits, post hoc PAS reclassification/protocol history, external validity, and several apparent table/statistical reporting errors.

## 2. Major points

1. **The conclusion should be tempered because the demonstrated benefit is mainly on a trial-defined/laboratory blood-loss endpoint, with little evidence of reduction in severe clinical outcomes.**  
   *Location:* Abstract lines 117-131; Outcomes, manuscript p. 8, lines 242-248; Results/Table 2, manuscript pp. 12 and 20; Discussion lines 379-383 and conclusion lines 421-423.  
   The primary outcome was “calculated estimated blood loss ≥1000 mL or red cell transfusion within 2 days,” not a directly measured or clinically adjudicated PPH outcome. Table 2 shows reduction in the composite (29.7% vs 35.1%; RR 0.83), calculated blood loss ≥1000 mL (25.7% vs 31.6%), and red cell transfusion within 2 days (18.8% vs 21.6%). However, other outcomes that matter greatly to women and clinicians were not clearly reduced: additional operations 58.3% vs 58.0%, hysterectomy 2.2% vs 2.1%, hypovolaemic shock 0.9% vs 0.9%, ICU/high-dependency transfer 13.4% vs 13.5%, open-label TXA 11.6% vs 12.1%, maternal thromboembolic events 0.1% vs 0.4%, and no maternal deaths. The abstract conclusion that TXA “resulted in a significant reduction of postpartum haemorrhage without increasing serious adverse events” should specify “trial-defined PPH” and should not imply proven reduction in severe morbidity. Please provide the overlap of the two primary-outcome components, absolute risk differences with CIs, and CIs for the NNTs, and explicitly state that the trial was not powered to detect differences in maternal death, hysterectomy, shock, thromboembolism, or other rare severe outcomes.

2. **Blood-loss ascertainment needs fuller reporting and sensitivity analyses.**  
   *Location:* Outcomes, manuscript p. 8, lines 242-248; Table 2, manuscript p. 20; supplementary table S5, appendix p. 9; Discussion lines 392-399.  
   The primary calculated blood loss depends on preoperative haematocrit “within 1 week” and postoperative haematocrit “closest to day 2,” with estimated blood volume as weight ×85. In a placenta praevia/PAS caesarean population, perioperative haemodilution, antepartum bleeding, intravenous fluid, transfusion before blood sampling, and the timing of the preoperative sample could materially affect calculated blood loss. The manuscript should report the distribution of timing of preoperative and postoperative haematocrit measurements, the body weight used and when it was measured, how many women required transfusion before the postoperative sample, and how many primary-outcome events were driven solely by calculated blood loss.  
   In addition, supplementary table S5 states that gravimetrically estimated blood loss was recorded “from placental delivery until the end of the caesarean delivery and within 24 hours after caesarean delivery.” In placenta praevia, important bleeding can occur before placental delivery, including at uterine incision or fetal delivery. Please clarify whether any pre-placental-delivery blood loss was captured. The discrepancy between calculated blood loss ≥1000 mL and gravimetric blood loss ≥1000 mL is substantial (placebo 31.6% vs 20.6%). Ref 24 supports that quantitative blood loss can be lower than calculated blood loss and only moderately correlated, but it studied vaginal delivery, not placenta praevia caesarean delivery. I would suggest adding sensitivity analyses using clinically measured/gravimetric blood loss plus transfusion, and reporting discordance between calculated and gravimetric classifications.

3. **The safety conclusion is too strong for the amount and duration of safety data.**  
   *Location:* Abstract lines 119-131; Adverse events, manuscript p. 12-13, lines 348-354; Table 3, manuscript p. 22; supplementary table S5 and S12; Table S8 VTE prophylaxis.  
   The trial observed only eight serious adverse events in the safety population (4 vs 4; RR 1.01, 95% CI 0.25 to 4.01), including 1 vs 3 thromboembolic events. This confidence interval is compatible with clinically important harm or benefit. Safety surveillance ended at 6 weeks and appears largely based on hospital records and telephone follow-up; by contrast, TRAAP2 assessed adverse events to 3 months because of postpartum thromboembolic risk (ref 7). The trial also excluded women with important thrombotic risk factors, recent LMWH/antiplatelet use, active cardiovascular/renal/liver disease, autoimmune disease, and severe antepartum bleeding (supplementary table S2), which limits safety inference in the broader placenta praevia/PAS population. Table S12 also has incomplete laboratory ascertainment for several safety labs. Please revise “without increasing serious adverse events” to “no increase was detected,” describe whether thromboembolic events were actively screened or symptom-driven, report SAE adjudication procedures, and discuss the limited power and follow-up duration for rare adverse events.

4. **The protocol history and post hoc PAS reclassification require much more transparent reporting.**  
   *Location:* Methods, manuscript p. 8, lines 190-196; supplementary protocol version history, protocol p. 5 / proof p. 53; SAP pp. 77-82.  
   The main manuscript says PAS cases were reviewed post hoc by two senior obstetricians with a third arbiter. The bound protocol version history states that, between October and December 2025, “in response to peer-review feedback,” the team re-evaluated PAS diagnostic accuracy and revised the PAS rate from 39.0% (661/1694) to 17.9% (303/1694), implying 358 overdiagnoses. This is important because PAS status is a prespecified subgroup and central to the trial’s claimed high-risk population. Please state in the main manuscript that PAS classification was revised after trial completion, whether reviewers were blinded to treatment allocation and outcomes, and whether the statistical analysis was locked before this reclassification. Please provide subgroup results using the original and adjudicated PAS classifications, or explain why only the adjudicated classification is valid. Editors should also be provided the protocol and SAP versions that were final before database lock/unblinding; the current bound protocol is dated Dec 16, 2025, after trial completion.

5. **Several table entries appear internally inconsistent and need a full statistical/reporting audit.**  
   *Location:* Table 2, manuscript p. 20; Table S11, appendix p. 17; Table S12, appendix p. 18.  
   Examples:  
   - Table 2 reports transfusion by discharge as 164/845 (19.4%) vs 185/849 (21.8%) but gives RR 0.85 with an implausibly narrow 95% CI of 0.85 to 0.86. The crude RR is about 0.89, and the CI cannot be that narrow.  
   - Table 2 gives mean gravimetric blood loss 790 vs 813 mL but a mean difference of –24.70 with CI –41.30 to 90.70; this looks like a sign or transcription error, especially because Table S11 gives a more plausible –22.9 (–89.45 to 43.62).  
   - Table S11 reports uterotonic use 774/831 (93.1%) vs 798/844 (94.5%) but RR 0.76; the crude RR is about 0.99. It also reports ICU/high-dependency transfer 111/831 vs 115/844 but RR 0.83.  
   - Table S12 reports alanine transaminase >2×ULN as 9 (1.4%) vs 71 (1.1%); 71/641 is not 1.1%, so this is likely a typo for 7.  
   These errors undermine confidence in the secondary and safety tables. Please regenerate all tables directly from the analysis outputs, check denominators, CIs, and model specifications, and confirm whether the primary outcome estimates are unaffected.

6. **Generalisability and the real-world comparator need fuller description.**  
   *Location:* Participants/exclusion criteria, manuscript p. 8, lines 197-202 and supplementary table S2; Procedures, manuscript p. 9, lines 232-240; Table 1 and Table S8; Limitations, manuscript p. 14, lines 410-418.  
   The authors acknowledge that comprehensive screening data and reasons for ineligibility were not collected. This is a major limitation because the trial excluded several groups common in severe placenta praevia/PAS care, including Hb ≤9 g/dL, estimated blood loss >500 mL within 12 hours before caesarean, recent LMWH/antiplatelet use, thrombophilia, thromboembolic history, renal/hepatic disease, and severe coagulation disorders. The comparator is also not simply oxytocin: 93-94% received uterotonics other than oxytocin by discharge, 52% received anticoagulant prophylaxis, and surgical management included local PAS approaches such as partial myometrial resection and relatively low hysterectomy rates. Please provide a screening flow diagram or, if unavailable, site-level recruitment denominators where possible; list which supplementary uterotonics were used, whether they were prophylactic or therapeutic, and timing relative to bleeding; and expand the discussion of applicability to emergency bleeding, anaemic patients, PAS-heavy populations, and settings with different transfusion/hysterectomy practices.

## 3. Minor points

1. **Citation accuracy for the stated 56% PPH incidence with PAS should be corrected.**  
   *Location:* Introduction lines 147-150; cited ref 4.  
   Ref 4 is a retrospective case-control study of singleton pregnancies with anterior placenta previa, prior caesarean, and prenatal suspicion of PAS, focused on massive transfusion. Its table shows postpartum haemorrhage in 241/430 overall, but it does not directly support the manuscript’s wording that PPH “escalat[es] to 56% in cases co-existing with PAS disorders.” Please cite a more directly applicable source or reword.

2. **Clarify trial registration date.**  
   *Location:* Abstract line 132; supplementary CONSORT table S15; ref 12.  
   The supplement lists ClinicalTrials.gov registration as March 31, 2023, whereas ref 12 reports March 15, 2023. Please reconcile.

3. **The title of ref 1 appears inaccurate.**  
   *Location:* Reference list.  
   The provided WHO document is titled *A Roadmap to combat postpartum haemorrhage between 2023 and 2030*, not “Roadmap for the prevention and management of postpartum haemorrhage (PPH).”

4. **Please report interaction P values and absolute risks for subgroup analyses.**  
   *Location:* Figure 2 and legend.  
   The statement that no significant variation was observed should be supported with interaction tests and event counts/risk differences, especially given the post hoc PAS reclassification and the post hoc antepartum haemorrhage subgroup.

5. **The discussion of body weight/BMI and the TRAAP2 comparison is speculative.**  
   *Location:* Discussion lines 384-391 and Table S14.  
   Because calculated blood loss directly uses weight ×85, body weight—not BMI per se—is the key variable. Please report actual body weight distributions and temper “highly supporting our speculation.”

6. **Clarify whether “transfer to intensive care unit” includes routine high-dependency observation.**  
   *Location:* Table 2 footnote.  
   The composite includes both ICU and obstetric high-dependency unit. Since 13.5% were transferred, this may reflect local practice rather than severe morbidity. Consider separating these in the main table.

7. **Language/typographical issues need copyediting.**  
   Examples include “confidence interval” misspelled in the protocol history, “cancealment” and “Blingding” in the CONSORT checklist, and “Wanq, Zilian” in the author metadata.

## 4. Anything you verified that checked out

1. **The primary outcome definition matches TRAAP2.**  
   Ref 7 defines postpartum haemorrhage after caesarean as calculated estimated blood loss >1000 mL or red-cell transfusion within 2 days, using estimated blood volume × haematocrit change / preoperative haematocrit.

2. **The TRAAP2 comparison numbers are accurately reported.**  
   Ref 7 reports the primary outcome in 26.7% vs 31.6% and adjusted RR 0.84 (95% CI 0.75 to 0.94), consistent with the manuscript’s comparison.

3. **The 2023 US trial is accurately described in broad terms.**  
   Ref 8 found no significant reduction in maternal death or blood transfusion by discharge/7 days (3.6% vs 4.3%; adjusted RR 0.89, 95.26% CI 0.74 to 1.07) and reported postpartum infectious complications of 3.2% vs 2.5% (RR 1.28, 95% CI 1.02 to 1.61), as discussed in the manuscript.

4. **The Cochrane review supports the existence of uncertainty about prophylactic TXA at caesarean delivery.**  
   Ref 9 included six RCTs, mostly in low-risk/high-resource settings, and found little to no difference in estimated blood loss ≥1000 mL and blood transfusion, with a slight reduction in calculated blood loss ≥1000 mL.

5. **The FIGO PAS criteria in supplementary table S1 are consistent with ref 15.**  
   The grade 1-3 clinical and histologic criteria in the appendix closely follow the FIGO classification.

6. **The Chinese two-child-policy prevalence claim is broadly supported.**  
   Ref 6 reports placenta previa prevalence increasing from 1.25% to 4.12% after implementation of the two-child policy in mainland China.

7. **The cited concern that quantitative/gravimetric blood loss may be lower than calculated blood loss is supported, with caveat.**  
   Ref 24 found quantitative blood loss was lower than calculated blood loss and only moderately correlated after vaginal delivery; the caveat is that this was not a placenta praevia caesarean population.

## 5. Editorial recommendation

**Major revision.** The trial addresses an important clinical question and the randomized, blinded design with near-complete primary outcome ascertainment is a major strength. However, the manuscript currently overstates the clinical and safety implications of a calculated blood-loss composite, does not adequately address limitations of blood-loss ascertainment, contains post-completion PAS reclassification that needs transparent handling, and includes multiple apparent numerical errors in tables. These issues do not necessarily invalidate the primary finding, but they must be corrected and the conclusions narrowed before the work can be judged reliable for a general medical audience.

## 6. What I could not assess

1. I could not verify the raw data, analysis code, database lock date, unblinding date, or whether the reported table errors are transcription errors versus analysis errors.  
2. I could not check ClinicalTrials.gov history or registry amendments because there is no internet access in this review environment.  
3. I could not assess whether PAS adjudicators were blinded to treatment and outcomes unless the authors report it.  
4. I could not assess site-level adherence to transfusion, uterotonic, surgical, or VTE prophylaxis protocols beyond what is in the manuscript and appendix.  
5. References 5 and 16 were not provided. I therefore could not verify claims relying on the unavailable Kanigalpula 2022 article or the Chinese-language placenta previa guideline.

===== TOKENS =====
api_calls=33  input=2682821 (cached=2497024)  output=12212  (reasoning=7282)  total=2695033
est_cost: $2.54 (cached@$0.50/M) .. $13.78 (upper bound) | dashboard authoritative

===== END (2026-06-03T22:00:52) =====